Skip to main
MDT
MDT logo

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 41 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 39%
Sell 0%
Strong Sell 2%

Bulls say

Medtronic's recent performance indicates a robust growth trajectory, particularly within its neuromodulation and diabetes product segments, as evidenced by a 6% market growth and a 240 basis point increase in market share for neuromodulation. The company's revenue is projected to grow between 3.4% and 3.8% for FY25, complemented by a non-GAAP EPS guidance of $5.44 to $5.50, reflecting a year-over-year increase of 10-11% excluding foreign exchange impacts. Furthermore, Medtronic's improvements in gross and operating margins, alongside significant revenue growth in diabetes products, support a favorable outlook for the company's financial health and market positioning.

Bears say

Medtronic's outlook is negatively impacted by anticipated revenue growth slowing to low-single digits, driven by unsuccessful new product launches and loss of market share in key product categories, coupled with flat or declining operating margins leading to below-consensus earnings. Additionally, the company faces various risks, including competition from new product launches, disappointing sales performance in sectors such as renal denervation and robotics, and adverse currency fluctuations, which could further strain financial performance. Recent financial metrics indicate a decline in R&D expense relative to sales, increasing SG&A expenses, and a slowdown in organic growth, all of which contributed to a significant drop in stock value.

Medtronic (MDT) has been analyzed by 41 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 39% suggest Holding, 0% advise Selling, and 2% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 41 analysts, Medtronic (MDT) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.